Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

Core Viewpoint - Eagle Pharmaceuticals, Inc. has appointed Abhinav "Abi" Jain as an independent member of its Board of Directors, which is part of a cooperation agreement with Nantahala Capital Management, a significant shareholder holding approximately 38% of the company's outstanding shares [1][2]. Group 1: Appointment Details - Abhinav Jain will serve as a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders [1]. - Jain will also be a member of the Board's Compensation Committee and Nominating and Corporate Governance Committee [1]. - The cooperation agreement includes provisions for the appointment of a second independent director by May 15, 2026 [1][3]. Group 2: Background of Abhinav Jain - Jain is currently an Analyst at Nantahala, focusing on investments in specialty and generic pharmaceuticals [2]. - Prior to Nantahala, he was an Associate at Angelo, Gordon & Co., where he concentrated on private equity and structured credit investments [2]. - Jain holds a degree in Chemical-Biological Engineering from the Massachusetts Institute of Technology and an M.B.A. with honors in Finance and Entrepreneurial Management from The Wharton School [2]. Group 3: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company involved in research and development, clinical, manufacturing, and commercial activities [4]. - The company is dedicated to developing innovative medicines aimed at improving patients' lives, with a portfolio that includes products like PEMFEXY®, RYANODEX®, and others [4]. - Eagle's pipeline includes oncology and critical care candidates targeting underserved therapeutic areas, with a focus on personalized medicine in cancer care [4].